Key result
Valsartan matches captopril post-MI, while combination therapy increases adverse events without survival benefit.
Why the study?
Does valsartan alone or combined with captopril improve survival compared to captopril in patients at high risk for cardiovascular events after myocardial infarction complicated by heart failure or left ventricular dysfunction?
Does valsartan alone or combined with captopril improve survival compared to captopril in patients at high risk for cardiovascular events after myocardial infarction complicated by heart failure or left ventricular dysfunction?
In patients with myocardial infarction complicated by heart failure or left ventricular dysfunction, valsartan is an effective alternative to captopril, but combination therapy causes harm without added survival benefit.
Answers are grounded in this paper and cite their sources.
Supports valsartan monotherapy as captopril alternative post-MI with HF/LV dysfunction; challenges dual blockade due to excess harm without survival gain.
Valsartan is as effective as captopril in patients who are at high risk for cardiovascular events after myocardial infarction. Combining valsartan with captopril increased the rate of adverse events without improving survival.
No takes yet. Share an insight, caveat, or question.
Pfeffer et al. (2003) studied this question. Valsartan was as effective as captopril in high-risk post-MI patients, whereas combining both increased adverse events without improving survival.
Synapse has enriched 10 related papers. Consider them for comparative context: